Education
About Us
Working with TipRanks
Follow Us
TScan Therapeutics (TCRX)
NASDAQ:TCRX
TCRX Stock Chart & Stats
$1.08
-$0.17(-5.65%)
At close: 4:00 PM EST
$1.08
-$0.17(-5.65%)
Day’s Range― - ―
52-Week Range$0.91 - $4.85
Previous CloseN/A
Volume150.47K
Average Volume (3M)964.74K
Market Cap
$61.29M
Enterprise Value$147.47M
Total Cash (Recent Filing)$184.45M
Total Debt (Recent Filing)$95.62M
Price to Earnings (P/E)―
Beta1.75
Next Earnings
Mar 11, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding52,471,405
10 Day Avg. Volume754,655
30 Day Avg. Volume964,741
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.41
Price to Sales (P/S)120.90
P/FCF Ratio-2.97
Enterprise Value/Market Cap2.41
Enterprise Value/Revenue6.74
Enterprise Value/Gross Profit7.84
Enterprise Value/Ebitda-0.43
Forecast
1Y Price Target
$5.50Price Target Upside409.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.23
Revenue Forecast (FY)$9.89M
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentUpdated Phase 1 data showed lower rates of relapse for patients on the TSC-101 arm compared to the control arm.
Financial StabilityTscan ended with $184.5M in cash and cash equivalents, guided to support operations into the second half of 2027.
Regulatory ProgressThe alignment with FDA on the pivotal study design for TSC-101, including an active-control arm, is seen as a positive development.
Bears Say
Investor ConcernsThe delay in expected TSC-101 launch and removal of the solid-tumor program, coupled with limited near-term catalysts, has moved the analyst to a neutral stance.
Program DeprioritizationTscan had deprioritized development of TCR-Ts in solid malignancies and enrollment in the PLEXI-T study was paused.
Workforce ReductionThe company announced a workforce reduction of approximately 30%, which is intended to extend the cash runway.
TScan Therapeutics News
TCRX FAQ
What was TScan Therapeutics’s price range in the past 12 months?
TScan Therapeutics lowest stock price was $0.91 and its highest was $4.85 in the past 12 months.
What is TScan Therapeutics’s market cap?
TScan Therapeutics’s market cap is $61.29M.
When is TScan Therapeutics’s upcoming earnings report date?
TScan Therapeutics’s upcoming earnings report date is Mar 11, 2026 which is in 93 days.
How were TScan Therapeutics’s earnings last quarter?
TScan Therapeutics released its earnings results on Nov 12, 2025. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.334 by $0.054.
Is TScan Therapeutics overvalued?
According to Wall Street analysts TScan Therapeutics’s price is currently Undervalued.
Does TScan Therapeutics pay dividends?
TScan Therapeutics does not currently pay dividends.
What is TScan Therapeutics’s EPS estimate?
TScan Therapeutics’s EPS estimate is -0.27.
How many shares outstanding does TScan Therapeutics have?
TScan Therapeutics has 52,471,405 shares outstanding.
What happened to TScan Therapeutics’s price movement after its last earnings report?
TScan Therapeutics reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.334. Following the earnings report the stock price went down -2.459%.
Which hedge fund is a major shareholder of TScan Therapeutics?
Currently, no hedge funds are holding shares in TCRX
TScan Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.50 (409.26% Upside)
$5.50 (409.26% Upside)
Blogger Sentiment
Bullish
TCRX Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-74.34%
12-Months-Change
Fundamentals
Return on Equity
-76.44%
Trailing 12-Months
Asset Growth
-24.65%
Trailing 12-Months
Company Description
TScan Therapeutics
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
TCRX Stock 12 Month Forecast
Average Price Target
$5.50
▲(409.26% Upside)
Technical Analysis
Zentalis Pharmaceuticals
―
ALX Oncology Holdings
―
Inhibikase Therapeutics
―
Surrozen
―
Instil Bio
―
Ownership Overview
20.20% Insiders
6.46% Mutual Funds
43.85% Other Institutional Investors
23.87% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---